Information  X 
Enter a valid email address

Flying Brands Ltd (IQAI)

  Print      Mail a friend

Thursday 27 September, 2018

Flying Brands Ltd

IB announce agreement to develop a diagnostic tool

RNS Number : 0651C
Flying Brands Limited
27 September 2018
 

Flying Brands Limited

("Flying Brands" or the "Company")

Imaging Biometrics announce agreement to develop a diagnostic tool for liver surface nodularity.

Imaging Biometrics®, LLC ("IB"), a subsidiary of Flying Brands Limited (LON:FBDU), announces today that it has been awarded a development contract by the Board of Trustees of the University of Alabama ("UAB") to develop a product to quantify liver surface nodularity ("LSN") - a biomarker derived from routine computed tomographic ("CT") images, which  allows prediction of cirrhosis decompensation and death. UAB will pay IB a fee to develop the software plus an additional fee for regulatory services.

In a paper published in "Radiology" in November 2016, the study's authors concluded that the LSN score derived from routine CT images allows prediction of cirrhosis decompensation and death. IB is seeking to translate these findings into a commercially robust software product that will streamline this process, and that will quickly and efficiently determine how well patients are responding to treatment. The agreement also includes preparing and submitting an application to the US FDA for obtaining regulatory market clearance.

Imaging Biometrics' CEO, David Smith said, "We believe this agreement could generate significant revenues for Imaging Biometrics. UAB's decision to enlist Imaging Biometrics as a development partner underscores their confidence in Imaging Biometrics' proven track record of commercialising advanced imaging technologies into routine clinical applications. We are excited about this opportunity and look forward to the possibility of entering into future agreements with UAB."  

About Imaging Biometrics

Imaging Biometrics, a subsidiary of Flying Brands Limited (LON:FBDU), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

Flying Brands Limited (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGRKMGZLKVZGRZM

a d v e r t i s e m e n t